Quantitative determination of biocytin in urine of patients with biotinidase deficiency using high-performance liquid chromatography (HPLC).
A specific method for the quantitative determination of biocytin from urine of biotinidase deficient patients is described using HPLC-separation and quantitative determination by an avidin binding method. Partial purification of biocytin from urine was achieved with an anion exchange resin and concentration of the eluate by lyophilization. The recovery of biocytin from urines was 95.3 +/- 5.9 (mean +/- SD). The precision of biocytin estimation in patients urines including the HPLC-sample preparation procedure varied between 5.9% and 10.5% (CV). Biocytin concentrations were measured in urine samples of 5 patients obtained during and/or before biotin therapy. Before treatment biocytin excretion ranged from 6.2-28.8 nmol/mmol creatinine. During therapy biocytin excretion increased to the 1.3 to 4-fold level in 3 out of 4 patients. However, there was no dose-related increase of biocytin excretion when pharmacological doses were administered. Apart from biocytin and biotin, patients excrete additional biotin derivatives. Some of these have been preliminary identified as bisnorbiotin and oxidation products of bisnorbiotin, biocytin and biotin.
Suormala
T M
TM
University Children's Hospital, Basel, Switzerland.
Baumgartner
E R
ER
Bausch
J
J
Holick
W
W
Wick
H
H
D000581:Amidohydrolases / Q000172:deficiency*; D001710:Biotin / Q000031:analogs & derivatives; D043523:Biotinidase; D002851:Chromatography, High Pressure Liquid; D005060:Europe; D006801:Humans; D008239:Lysine / Q000031:analogs & derivatives* / Q000652:urine; D012015:Reference Standards
D001710:Biotin; D000581:Amidohydrolases; D043523:Biotinidase; C013411:biocytin; D008239:Lysine